Katalog der Deutschen Nationalbibliothek

Gesamter Bestand

Musikarchiv

Exilsammlungen

Buchmuseum

Suchformular zurücksetzen

Expertensuche ?

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

Dienstag 18. November 2025: Die Lesesäle der Deutschen Nationalbibliothek in Frankfurt am Main öffnen wegen einer Personalversammlung erst ab 13 Uhr. // Tuesday 18 November 2025: The reading rooms of the German National Library in Frankfurt am Main will open at 13:00 due to a staff assembly.

Mittwoch, 19. November 2025: Die Deutsche Nationalbibliothek in Leipzig ist geschlossen.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

111 - 120 von 127

	111	Kein Nachteil durch Wechsel zwischen Biosimilar und Originator Enthalten in Hautnah / Dermatologie Bd. 34, 12.5.2018, Nr. 3, date:5.2018: 28-29
	112	Label discrepancies between originator and generic drugs impact safety Enthalten in Reactions weekly Bd. 1802, 2.5.2020, Nr. 1, date:5.2020: 8
	113	Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies Enthalten in Advances in therapy Bd. 35, 6.8.2018, Nr. 9, date:9.2018: 1295-1332
	114	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent Enthalten in BioDrugs Bd. 32, 29.9.2018, Nr. 5, date:10.2018: 397-404
	115	Originator-to-biosimilar non-medical switch may not yield such great cost savings Enthalten in PharmacoEconomics & outcomes news Bd. 892, 27.11.2021, Nr. 1, date:11.2021: 17
	116	Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries Enthalten in Rheumatology and therapy Bd. 10, 12.1.2023, Nr. 2, date:4.2023: 433-445
	117	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists Enthalten in BioDrugs Bd. 31, 19.9.2017, Nr. 5, date:10.2017: 447-459
	118	Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab Enthalten in BioDrugs Bd. 27, 7.5.2013, Nr. 5, date:10.2013: 495-507
	119	Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia Enthalten in BMC Rheumatology Bd. 6, 27.1.2022, Nr. 1, date:12.2022: 1-9
	120	Safety evaluation of infliximab originator and biosimilars Enthalten in Reactions weekly Bd. 1727, 10.11.2018, Nr. 1, date:11.2018: 11